Exit
Register
Login
2025 MaTOS Lung | Session IX | Targeted Therapy Forum-Part I Case-Based Panel Discussion
Case #1: Progression After Third Generation EGFR TKI
Case #2: Treatment of Uncommon EGFR Mutations
Case #3: First Line Therapy for ALK Positive Lung Cancer
Case #4: Treatment Beyond Lorlatinib in ALK Positive Lung Cancer
Case #5: Never Smoker with No Driver Alteration
Wrap-up Session
Finish Course
You need to enroll in this course to view this chapter
This chapter is locked
Case #2: Treatment of Uncommon EGFR Mutations
Enroll for $5,000.00
0% Course Complete